Session » (0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0700

A Population-Based Study of Vasculitis Among Farmers and Urban Residents in Alberta

9:00AM-11:00AM: Abstract Number: 0697

Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 0706

Aortitis and Periaortitis Spectrum in 135 Patients from a Single Referral Centre

9:00AM-11:00AM: Abstract Number: 0696

Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study

9:00AM-11:00AM: Abstract Number: 0692

Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity

9:00AM-11:00AM: Abstract Number: 0703

Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis

9:00AM-11:00AM: Abstract Number: 0721

Characterization of Numeric Rating Scales for Symptom Assessment in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 0718

Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting

9:00AM-11:00AM: Abstract Number: 0712

Clinical and Histologic Prognostic Factors of Renal Progression in Adults with IgA Vasculitis

9:00AM-11:00AM: Abstract Number: 0704

Clinical Characteristics and Outcomes in Patients Found to Have Clinically Isolated Aortitis After Aortic Aneurysm Repair: A Single-Center Experience

9:00AM-11:00AM: Abstract Number: 0720

Cognitive Function and Its Associated Factors in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 0693

Comparison of the Cardiovascular Risk in Patients with Vasculitis and Diabetes Mellitus

9:00AM-11:00AM: Abstract Number: 0698

Differentiating Large Vessel Vasculitis from Vasculitis Mimickers in a Real World Setting: Clinical Presentation, Laboratory Tests and Radiographic Findings

9:00AM-11:00AM: Abstract Number: 0716

Efficacy of Immunosuppressants for Disease Relapse in Patients with IgG4-related Disease at Our Institution

9:00AM-11:00AM: Abstract Number: 0715

Glucocorticoid Toxicity in Patients with IgG4-Related Disease Within the First Year of Treatment

9:00AM-11:00AM: Abstract Number: 0711

IgA Vasculitis in a Diverse Adult Patient Population

9:00AM-11:00AM: Abstract Number: 0713

IgG4-Related Disease as a Potencial Etiology of Idiopathic Constrictive Pericarditis

9:00AM-11:00AM: Abstract Number: 0695

Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study

9:00AM-11:00AM: Abstract Number: 0701

Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study

9:00AM-11:00AM: Abstract Number: 0702

Large Vessel Vasculitis Increases Risk of Acute Myocardial Infarction in Patients Admitted for Congestive Heart Failure : A Nationwide Inpatient Database Study

9:00AM-11:00AM: Abstract Number: 0717

Mitochondria-mediated Platelet Activation in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 0708

NFKB1 and NFKBIA: Relevant Players in the Pathogenesis of IgA Vasculitis?

9:00AM-11:00AM: Abstract Number: 0694

Off-label Use of Biologics in Urticarial Vasculitis: A European Cohort Study

9:00AM-11:00AM: Abstract Number: 0719

Polymyalgia Rheumatica Following SarsCOV-2 Vaccination: A Single Center Cohort Study

9:00AM-11:00AM: Abstract Number: 0707

Prevalence and Distribution of Vascular Calcifications at CT Scan in Patients with Large Vessel Vasculitis and Patients with Lymphoma: A Matched Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 0691

Recognizing the New Disorder “Idiopathic Hypocryoglobulinaemia” in Patients with Previously Unidentified Clinical Conditions

9:00AM-11:00AM: Abstract Number: 0714

Single Center Experience of Rituximab Treatment for IgG4-RD Disease in a Large Multi-ethnic Cohort

9:00AM-11:00AM: Abstract Number: 0705

Sleep Disturbances in Patients with Vasculitis: Results of the Vasculitis Patient-Powered Research Network Sleep Study (SleepVasc)

9:00AM-11:00AM: Abstract Number: 0709

Survival of Adults with IgA Vasculitis

9:00AM-11:00AM: Abstract Number: 0699

T Cell Subset Analysis in Patients with Large-Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 0710

The Association of IgA Vasculitis and Malignancy in Adults: A Systematic Review

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].